NU SKIN ENTERPRISES, INC. (NUS) stock intrinsic value fair value estimate & owner earnings analysis

Nu Skin Enterprises sells anti-aging skincare (its ageLOC line) and nutritional/wellness products (Pharmanex) through a network of independent sales affiliates, using a modified employee-based selling model in Mainland China where local rules restrict traditional direct selling. In recent years the company has also built a family of smaller, mostly acquired businesses it calls Rhyz, including a skincare-device retailer and, until its January 2025 sale, an affiliate-marketing platform called Mavely. The core business remains in a multi-year decline that has not leveled off and, as of the most recent quarter, has become more broad-based rather than less. Revenue fell from a pandemic-era peak of about $2.7 billion in 2021 to about $1.5 billion in 2025, and was down roughly 15% year-over-year again in the first half of 2026. In the second quarter of 2026, every major region declined by a double-digit percentage: Mainland China (-14%), Southeast Asia/Pacific (-15%), Japan (-14%), and the Americas (-18%, now the weakest region rather than the strongest). Paid sales affiliates fell 8% and total customers fell 14% year-over-year in that quarter - the leading indicators behind the revenue trend show no sign of bottoming yet. The Rhyz diversification has so far destroyed value rather than created it: the company recorded a $181 million impairment in 2024 and a further roughly $79 million impairment in the second quarter of 2026, both tied to acquired businesses and goodwill. Also in the second quarter of 2026, the company recorded a $167.5 million non-cash charge reserving against previously recognized tax benefits (a "valuation allowance") - an accounting step taken only when a company's own auditors conclude it is no longer more likely than not that enough future taxable profit will be earned to use those benefits. That is a real, filed statement by management about its own reduced confidence in near-term profitability, and we have weighted it in our downside case. Neither charge affects the company's actual cash generation, which is the basis for our value estimate, but both speak to the business's trajectory. On the plus side, lenders remain supportive: the company renewed its credit facilities for a new five-year term in 2026. Cash of about $190 million now sits slightly below total debt of about $214 million (a modest, not alarming, increase in leverage after cash use in the first half of the year). There is also a genuine, quantified new product platform: a connected skincare device called Prysm iO had over 39,000 units placed as of the second quarter of 2026 (up 30% in a single quarter), with more than 2.5 million skin scans logged and a target of 50,000-60,000 placements by year end. Core gross margin also improved to 77.7% on price increases and supply-chain efficiency, and quarterly general and administrative costs fell $15.9 million year over year, with more savings promised from a planned 2027 reorganization. We estimate the company's underlying, ongoing cash-generating power - cash from operations, adjusted to remove working-capital swings, stock-based compensation, and only the capital spending needed to sustain (not grow) the business - at roughly $1.82 per share for 2025, in line with the median of the last three completed fiscal years. Two accounting judgments matter here. First, the impairments and the tax charge are non-cash and are already excluded from this figure through the normal cash-flow adjustment - we have not double-counted them as a cost, but we have let the pattern of repeated write-downs on acquired businesses weigh on our downside case rather than assuming it won't recur. Second, the company's incentive-accrual liabilities to its sales force have shrunk in each of the last five years, which we have treated, per our standard method, as an ordinary working-capital swing rather than a permanent cost - though given the continuing decline in the affiliate count, that treatment could prove too generous if the pattern continues, and we flag it as a judgment call rather than a certainty. Our bear case assumes the broad, double-digit regional declines and affiliate attrition seen through mid-2026 continue for several more years before gradually easing, the Rhyz ventures keep needing occasional further write-downs rather than becoming a real contributor, and the company's largely fixed overhead cannot shrink as fast as revenue - even after two earlier rounds of cost-cutting already captured the easier savings. Per-share earning power falls from about $1.82 today to roughly $0.53 by around the seventh year and settles there. We estimate the shares would be worth about $11.01 today under this outcome. Our base case assumes the decline continues through the rest of 2026 roughly in line with the company's own published outlook, then keeps gradually easing as the cost actions already underway (the gross-margin and G&A gains noted above) roughly offset the effect of a still-shrinking sales force, so the business settles into a smaller, largely flat footprint by around 2032. Per-share earning power settles at roughly $1.20. We estimate the shares are worth about $20.17 today under this middle-of-the-road outcome; more than half of that value reflects the business continuing indefinitely at that smaller size, which remains the single biggest judgment call in this analysis. Our bull case assumes the Prysm iO device platform keeps scaling as guided, the gross-margin and cost-saving gains persist and are joined by the larger, currently unquantified savings management has guided for 2027, the decline arrests within about two to three years, and the business finds modest, low-single-digit growth for several years thereafter before leveling off around $2.13 per share of earning power - not a return to the industry's earlier growth era, just a stabilized, somewhat more efficient version of today's business. We estimate the shares would be worth about $34.42 today under this outcome. This is a business with a real, unresolved risk that today's decline does not stabilize - a risk large enough that even our base case does not serve as the margin-of-safety price. The margin-of-safety price is about $6.50 per share, a level that still leaves a substantial cushion against our downside case. The margin-of-safety price would move closer to the base-case level only once the trend actually turns: specifically, two or more consecutive quarters in which the year-over-year revenue decline meaningfully improves from the roughly 15% pace of the first half of 2026, and the paid-affiliate and customer counts stop falling at a similar pace. What would have to be true for our downside case to be wrong: the regional revenue declines and affiliate attrition seen through mid-2026 would need to keep easing rather than persisting, and the new device platform and cost program would need to keep delivering the early results management has reported. We did not find anything in the filings we could not reconcile, though the very large swing in reported net income this year - driven mostly by the impairment and tax charges described above, not by cash generation - is worth understanding before looking at net-income-based figures elsewhere.